LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SEER
Seer, Inc.
There isn't enough reported data to score SEER yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SEER Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
SEER's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | โ |
| Current | 46x | $1,427 | โ |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SEER PE Valuation
SEER has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SEER Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SEER's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SEER on earnings quality, reporting a profit while its opponent remains loss making.
SEER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | +$0.21 |
| Q2 2026 | -$1.22 | +$0.17 |
| Q1 2026 | -$1.24 | +$0.17 |
| Q4 2025 | -$1.28 | +$0.11 |
| Q3 2025 | -$1.36 | -$0.07 |
| Q2 2025 | -$1.39 | -$0.12 |
| Q1 2025 | -$1.41 | -$0.12 |
| Q4 2024 | -$1.39 | -$0.04 |
SEER is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.49 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SEER on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SEER on profitability, with a higher operating margin.
SEER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | +0.3% |
| Q2 2026 | $3.1M | -21% |
| Q1 2026 | $2.8M | -33% |
| Q4 2025 | $4.2M | +5% |
| Q3 2025 | $4M | -1.6% |
| Q2 2025 | $3.9M | +28% |
| Q1 2025 | $4.1M | +35% |
| Q4 2024 | $4M | -9.9% |
SEER's revenue is down over the past year, though its latest quarter was up: $4M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -368% | +119 points |
| Q2 2026 | -543% | -21 points |
| Q1 2026 | -618% | -118 points |
| Q4 2025 | -414% | +173 points |
| Q3 2025 | -487% | +116 points |
| Q2 2025 | -522% | +360 points |
| Q1 2025 | -500% | +322 points |
| Q4 2024 | -587% | -86 points |
SEER's operating margin was โ368% last quarter, up 119 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SEER on cash generation, producing positive trailing cash flow while its opponent burns cash.
SEER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10M | -$2.1M |
| Q2 2026 | -$9.6M | +$5.6M |
| Q1 2026 | -$15.7M | -$3.6M |
| Q4 2025 | -$11.1M | -$178K |
| Q3 2025 | -$7.8M | +$8.5M |
| Q2 2025 | -$15.2M | -$4M |
| Q1 2025 | -$12.1M | -$861K |
| Q4 2024 | -$10.9M | +$1.1M |
SEER has burned cash in almost every quarter: โ$46M over the past year, against โ$46M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SEER Net Leverage
SEER's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SEER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 4.7 | Oversold |
SEER's weekly RSI is 39 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SEER PE vs Healthcare Sector
SEER has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SEER on trend strength, trading above more of its moving averages.
SEER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.91 | 17% below |
| 20 week MA | $1.97 | 19% below |
| 50 week MA | $1.88 | 15% below |
| 100 week MA | $2.00 | 20% below |
| 200 week MA | $2.32 | 31% below |
SEER is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SEER on returns for 2026, with the stronger performance.
SEER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $56.5 | $62.0 | +9.9% |
| 2021 | $62.0 | $23.8 | -62% |
| 2022 | $23.8 | $5.65 | -76% |
| 2023 | $5.65 | $1.94 | -66% |
| 2024 | $1.94 | $2.26 | +16% |
| 2025 | $2.26 | $1.84 | -19% |
| 2026 YTD | $1.84 | $1.59 | -14% |
SEER has finished lower in four of the last six years. It's down 14% so far in 2026.